



FOR IMMEDIATE RELEASE

Contacts:

For Ohmx Corporation:

Dimitra Georganopoulou

Tel: (847) 491-8513

Fax: (847) 491-8510

dimitra@ohmx.com

NCI-NIH awards Ohmx \$208,110 in Phase I SBIR Grant

Evanston IL, September 27th 2010 – Ohmx Corporation, a bioelectronic detection company focused on developing a near-patient analyzer for monitoring of chronic diseases, is pleased to announce that it was awarded a 9 month, \$208,110 Phase I SBIR grant from the National Cancer Institute (NCI). Ohmx Corporation will be working together with Dr. William Catalona during this feasibility study to evaluate the scientific and technical merit of Ohmx's latest technology for prostate cancer detection.

About the Company:

Ohmx is advancing e-Diagnostics by developing a home monitoring device that can quantify clinical biomarkers and other important disease indicators from a finger prick. Ohmx's handheld monitoring device is electronic, low-cost, user-friendly, contains advanced communications protocols and can be used as a near-patient analyzer in the convenience of the patient's home. Except for diabetes, there are few consumer devices that can monitor chronic diseases. Ohmx systems address this unmet need by offering a comprehensive platform for tests routinely used for chronic disease monitoring, including cardiac markers, blood gases, electrolytes, metabolites, lipids, cholesterol, glucose, glycosylated serum proteins and hemoglobin. Ohmx was founded by NU Prof. Thomas Meade, PhD, who sold his prior company to Motorola for \$300MM; President & CEO is Barbara Dyson and R&D is headed by Dimitra Georganopoulou, PhD (Inverness, Nanosphere). Ohmx seeks to raise \$10MM to fund ongoing product development, manufacturing, and product launch. The Company has raised \$7.6MM to date.

This press release contains forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.